This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohn, J. S. Articles by Davignon, J. Search for Related Content PubMed PubMed Citation Articles by Cohn, J. S. Articles by Davignon, J. Related Collections Pathophysiology Risk Factors Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2474-2486.)
© 1999 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Detection, Quantification, and Characterization of Potentially Atherogenic Triglyceride-Rich Remnant Lipoproteins

Jeffrey S. Cohn; Caroline Marcoux; Jean Davignon

From the Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Montreal, Quebec, Canada.

Correspondence to Jeffrey S. Cohn, Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, 110 Pine Ave W, Montreal, Quebec, Canada H2W 1R7. E-mail cohnj{at}ircm.qc.ca

	Abstract

Top Abstract Introduction Difficulties in Detecting and... Remnant Lipoproteins Separated... Remnant Lipoproteins Separated... Separation of Remnant... Identification of Remnant... Quantification of Remnant... Remnant Lipoproteins Separated... Physical or Biochemical... Conclusions References

 
Abstract—Triglyceride-rich lipoprotein (TRL) remnants are formed in the circulation when apolipoprotein (apo) B-48–containing chylomicrons of intestinal origin or apoB-100–containing VLDL of hepatic origin are converted by lipoprotein lipase, and to a lesser extent by hepatic lipase, into smaller and more dense particles. Compared with their nascent precursors, TRL remnants are depleted of triglyceride, phospholipid, and C apolipoproteins and are enriched in cholesteryl esters and apoE. They can thus be identified, separated, and/or quantified in plasma according to their density, charge, size, specific lipid components, apolipoprotein composition, and/or apolipoprotein immunospecificity. Each of these approaches has contributed to our current understanding of the compositional characteristics of TRL remnants and their potential to promote atherosclerosis. An ongoing search is nevertheless under way for more accurate and clinically applicable remnant lipoprotein assays that will be able to better define coronary artery disease risk in patients with hypertriglyceridemia.

Key Words: atherogenesis • triglycerides • apolipoproteins • lipoproteins • assay

	Introduction

Top Abstract Introduction Difficulties in Detecting and... Remnant Lipoproteins Separated... Remnant Lipoproteins Separated... Separation of Remnant... Identification of Remnant... Quantification of Remnant... Remnant Lipoproteins Separated... Physical or Biochemical... Conclusions References

 
Increasing experimental and clinical evidence suggests that triglyceride-rich lipoproteins (TRL) play a significant role in the pathogenesis of atherosclerosis.^{1 2 3} The value of measuring plasma triglyceride concentration and of treating patients with hypertriglyceridemia is therefore becoming more widely accepted.^{4 5 6 7} Epidemiological studies, however, have often failed to identify plasma triglyceride concentration as an independent risk factor for coronary artery disease (CAD).⁸ Despite a strong univariate association between plasma triglyceride levels and risk of CAD, this relationship often fails to reach statistical significance when other lipid risk factors, such as HDL cholesterol, are taken into account. Several reasons can be put forth to explain this phenomenon. First, plasma triglyceride concentration increases and decreases throughout the day in response to the ingestion of frequent meals. Even if measured after a 10- to 12-hour overnight fast (as is normal clinical practice), triglyceride levels vary considerably more than LDL and HDL cholesterol levels, with day-to-day biological variability being 23%, 9.5%, and 7% for triglyceride, LDL, and HDL cholesterol levels, respectively.⁹ Second, there is a strong metabolic interdependence between the levels of different plasma lipids and lipoproteins, and a significant mathematical correlation consequently exists between different lipoprotein parameters. This is particularly exemplified by the strong inverse correlation between levels of total triglyceride and HDL cholesterol,¹⁰ which thwarts attempts to assign statistically significant independence for these parameters. Third, plasma triglyceride is carried in a number of different lipoproteins (eg, chylomicrons, large and small VLDL, and chylomicron and VLDL remnants), and the ability of different triglyceride-rich lipoproteins to promote atherosclerosis is not the same.

Differences in the potential atherogenicity associated with different types of TRL is best illustrated by the prevalence of premature CAD in patients with different inherited forms of hypertriglyceridemia. Type I or type V hyperlipoproteinemic patients have extremely high triglyceride levels caused most commonly by lipoprotein lipase or apolipoprotein (apo) C-II deficiency, and they have a significant increase in circulating levels of very large TRL. They are not, however, at greatly increased risk of CAD.¹¹ In contrast, type III hyperlipoproteinemic patients have more moderate hypertriglyceridemia caused by reduced hepatic uptake of TRL remnants and subsequent accumulation in plasma of ß-VLDL, and they do have an increased risk of CAD and peripheral vascular disease.¹² Smaller, partially catabolized TRL (TRL remnants) are thus believed to be more atherogenic or thrombogenic than larger, newly-secreted TRL. This is supported by experimental data showing the following: (1) smaller remnant particles can diffuse into the arterial intima, whereas large chylomicrons and VLDL (diameter >75 nm) are excluded from entering the vessel wall¹³ ; (2) due to their reduced size, increased apoE content, and association with lipoprotein lipase, TRL remnants are more likely to be retained by heparan sulfate proteoglycans within the arterial intima¹⁴ ;(3) TRL-induced cholesteryl ester accumulation by macrophages is dependent on the exposure of apoE epitopes through lipolysis of TRL¹⁵ ; (4) lipoprotein lipase–mediated generation of TRL remnants results in the formation of lipolytic products, which are cytotoxic to macrophages¹⁶ and which can increase endothelial cell layer permeability¹⁷ ; and (5) increased activity of coagulation factor XII in patients with hypertriglyceridemia is dependent on TRL lipolysis.¹⁸

	Difficulties in Detecting and Isolating TRL Remnants

Top Abstract Introduction Difficulties in Detecting and... Remnant Lipoproteins Separated... Remnant Lipoproteins Separated... Separation of Remnant... Identification of Remnant... Quantification of Remnant... Remnant Lipoproteins Separated... Physical or Biochemical... Conclusions References

 
TRL remnants are formed in the circulation when apoB-48–containing chylomicrons of intestinal origin or apoB-100–containing VLDL of hepatic origin are converted by lipoprotein lipase (and to a lesser extent by hepatic lipase) into smaller and more dense particles.¹⁹ Compared with their nascent precursors, TRL remnants are depleted of triglyceride, phospholipid, and apoCs (and apoA-I and apoA-IV in the case of chylomicrons) and are enriched in cholesteryl esters and apoE.^{20 21} They can thus be identified, separated, or quantified in plasma on the basis of their density, charge, size, specific lipid components, apolipoprotein composition, or apolipoprotein immunospecificity²² (Table). Each of these approaches has provided useful information about the structure and function of remnant lipoproteins and has helped to establish the role of TRL remnants in the pathogenesis of atherosclerosis. Accurate measurement and characterization of plasma remnant lipoproteins, however, has proven to be difficult for the following reasons: (1) despite their reduced size and triglyceride content, they are difficult to differentiate from their triglyceride-rich precursors; (2) due to their rapid plasma catabolism, they exist in plasma at relatively low concentrations; and (3) because remnants are at different stages of catabolism, they are very heterogeneous in size and composition. This latter characteristic is illustrated in Figure 1, in which TRL become progressively smaller, more dense, and less negatively charged as they are converted to TRL remnants. They gradually lose triglyceride and, in relative terms, become enriched in cholesteryl ester. They also lose their complement of C apolipoproteins (apoC-I, apoC-II, and apoC-III), which are replaced by apoE. At any given time, there is a continuous spectrum of different-sized remnants in the blood. Some of these particles are of intestinal origin. They contain apoB-48 and are more numerous after a fat-rich meal. The majority, however (in both the fed and fasted state), contain apoB-100 and are derived from the liver. Depending on the extent to which they have been lipolyzed, both species of TRL contain different proportions of triglyceride and cholesterol and may or may not contain apoCs or apoE. Remnant lipoproteins are thus structurally and compositionally diverse, which has made it necessary to use different biochemical techniques for the detection, quantification, and characterization of these lipoproteins.

View this table: [in this window] [in a new window]   Table 1. Biochemical Criteria Used to Separate and Quantify TRL Remnants and Reference to Studies Linking These Remnant Parameters to CAD

View larger version (44K): [in this window] [in a new window]   Figure 1. TRL and their remnants are structurally and compositionally heterogeneous, which confounds attempts to separate them solely on the basis of their size, density, or compositional characteristics. De novo synthesized apoB-48–containing chylomicrons of intestinal origin, or apoB-100–containing VLDL of hepatic origin are converted by lipoprotein lipase (and to a lesser extent by hepatic lipase) into a whole spectrum of smaller, more dense, and less negatively-charged particles (as indicated diagrammatically). Intestinal chylomicrons very rapidly lose their apoA-I and apoA-IV components after being secreted into the circulation from the lymphatics. As chylomicrons and VLDL are lipolyzed, they lose their C apolipoproteins (C-I, C-II, and C-III) and gain apoE. TRL remnants therefore contain apoB-100 or apoB-48 (depending on their origin) and contain apoCs, apoE, or both (depending on their extent of hydrolysis). TG indicates triglycerides; Chol, cholesterol; and Rel, relatively.

	Remnant Lipoproteins Separated According to Density

Top Abstract Introduction Difficulties in Detecting and... Remnant Lipoproteins Separated... Remnant Lipoproteins Separated... Separation of Remnant... Identification of Remnant... Quantification of Remnant... Remnant Lipoproteins Separated... Physical or Biochemical... Conclusions References

 
The traditional method for isolating TRL remnants is by ultracentrifugation, whereby analytical, sequential, or density gradient ultracentrifugation has been used to isolate lipoproteins intermediate in density (1.006<d<1.019 g/mL, S_f 12 to 20) between VLDL and LDL.²³ IDL concentration in plasma has been measured in terms of IDL total mass, cholesterol, triglyceride, or apoB. In normolipidemic subjects, the plasma concentration of IDL cholesterol is 5 to 15 mg/dL, and the total mass of IDL is 10 to 30 mg/dL.^{24 25 26} Under normal circumstances, 3% to 10% of total plasma cholesterol is thus isolated as IDL cholesterol, whereas in patients with significant plasma remnant lipoprotein accumulation (type III hyperlipoproteinemics), 15% to 20% of total plasma cholesterol is isolated as IDL.²⁷ Individuals with combined hyperlipidemia tend to have higher levels of IDL cholesterol than those with hypertriglyceridemia or hypercholesterolemia alone (18.8±4.7 versus 15.6±4.7 versus 11.4±7.9 mg/dL, respectively),²⁶ and patients with familial hypercholesterolemia (FH) have significantly higher IDL levels than control subjects, although there is no significant difference between IDL levels in FH heterozygotes and homozygotes.²⁴ In normolipidemic subjects, lipoproteins in the IDL fraction have a hydrated particle diameter of 27.5 to 30 nm and contain 10% to 20% triglyceride, 40% to 50% cholesterol, 21% phospholipid, and 18% protein.²⁸ The majority of IDLs have a charge similar to that of LDL. More than 90% of IDL protein is composed of apoB-100, and in relative terms, this fraction contains only small amounts of apoE and apoCs.

Although IDL cholesterol concentration is the parameter most widely used in research laboratories to assess plasma remnant lipoprotein concentration, there is no standardized clinical procedure for its measurement. Probably the most accurate approach is to simultaneously centrifuge a sample of serum or plasma at d=1.006 g/mL and a second aliquot at d=1.019 g/mL. IDL cholesterol can then be calculated as the difference between cholesterol in the d>1.006 and d>1.019 g/mL fractions. Unfortunately, this means that 2 relatively large, experimentally-determined numbers are subtracted to obtain a considerably smaller number, which then has an inherently large experimental error. The precision of this assay is therefore less than optimal, and variability between laboratories can be high. Ultracentrifugation also requires costly and specialized equipment that is not readily available in all clinical laboratories. It also must be recognized that the IDL fraction represents a collection of cholesterol-enriched, triglyceride-depleted remnant particles that does not include larger, more triglyceride-rich, less completely catabolized remnants having a density <1.006 g/mL. Small VLDL (S_f 20 to 60) have been shown by in vivo kinetic studies to be derived from large VLDL²⁹ and to be of similar, if not greater, pathophysiological significance than IDLs.^{30 31} For this reason, IDLs have sometimes been defined as lipoproteins in the S_f 12 to 60 range.

Numerous cross-sectional studies have demonstrated that patients with CAD tend to have increased plasma IDL levels.^{25 30 32 33 34 35} The first of these studies was published in 1950 and showed that the incidence of measurable concentrations of lipoproteins in the S_f 10 to 20 range was significantly higher in 20- to 40-year-old men compared with females of the same age, subjects >40 years of age compared with younger subjects, diabetic versus nondiabetic subjects, and patients proven to have had a myocardial infarction (MI) compared with control subjects.³² Japanese male and female survivors of acute MI (n=97) similarly had increased IDL (1.006<d<1.019 g/mL) triglyceride and cholesterol levels,³³ and Canadian men with objectively documented CAD were found to have significantly higher IDL (S_f 12 to 60) triglyceride and apoB levels than subjects free of disease.³⁰ Multivariate analysis demonstrated that CAD was independently related to smoking and IDL levels. Individuals who smoked had higher IDL levels than nonsmokers, although the association between IDL levels and CAD did not appear to depend on smoking.³⁰

Plasma concentrations of IDL have been related to the extent and severity of angiographically-assessed coronary artery atherosclerosis in both cross-sectional^{34 35} and longitudinal studies.^{31 36 37 38} Serum total IDL (S_f 12 to 20) mass concentrations were measured by analytical ultracentrifugation in a subset of 57 male subjects in the National Heart, Lung, and Blood Institute Type II Coronary Intervention Study,³⁶ in which treatment of hypercholesterolemic subjects with diet and cholestyramine resin for 5 years resulted in reduced progression of CAD, as assessed by angiography.³⁹ Changes in IDL levels measured over 2 years were strongly associated with the extent of progression of CAD in both drug- and placebo-treated subjects. Changes in IDL mass and ratios of HDL to total cholesterol or HDL to LDL cholesterol were inversely correlated and had a similar ability to predict disease progression.³⁶ IDL cholesterol levels were also measured at repeated intervals during the 3 year duration of the St. Thomas' Atherosclerosis Regression Study (STARS).⁴⁰ Seventy-four hypercholesterolemic men with CAD completed treatment with placebo, diet alone, or diet plus cholestyramine. Mean absolute width of angiographically assessed coronary segments increased significantly in the active-treatment groups. Improvement in CAD was inversely related to in-trial IDL and LDL cholesterol levels and positively related to in-trial HDL cholesterol levels, although multiple linear regression analysis did not identify IDL as a significant independent predictor of disease.³⁷ In a somewhat larger study³⁸ (272 men and 63 women) with a follow-up period of 4 to 6 years, IDL cholesterol was found to have a significant positive correlation and HDL cholesterol a significant negative correlation with 2-year difference in mean percentage diameter of coronary artery stenoses. Remnant lipoprotein cholesterol concentration (defined as the sum of cholesterol in IDL plus estimated remnant cholesterol in VLDL) was found to be independently associated with progression of CAD, as well as with ischemic cardiovascular events; a 1 mg/dL increase in remnant cholesterol concentration was associated with a 2% increase in the possibility of a cardiovascular event. These findings are in turn supported by results from the Monitored Atherosclerosis Regression Study (MARS), in which middle-aged men and women were randomized to treatment with lovastatin or placebo. Coronary artery lesion progression was found to be independently correlated with plasma concentrations of small VLDL (S_f 20 to 60) (as well as inversely with HDL₃),³¹ whereas the increase in carotid intima-media thickness was independently correlated with IDL levels (S_f 12 to 20).⁴¹

	Remnant Lipoproteins Separated According to Their Charge

Top Abstract Introduction Difficulties in Detecting and... Remnant Lipoproteins Separated... Remnant Lipoproteins Separated... Separation of Remnant... Identification of Remnant... Quantification of Remnant... Remnant Lipoproteins Separated... Physical or Biochemical... Conclusions References

 
Plasma lipoproteins have routinely been separated according to their charge by agarose gel electrophoresis. Large TRL of intestinal origin (chylomicrons) remain at the origin of the gel, while ultracentrifugally-isolated VLDL (d<1.006 g/mL) normally migrate as a single band with pre-ß mobility (Figure 2). Smaller, less-triglyceride-rich VLDL are less negatively charged and migrate with slower mobility.^{12 42} They often appear as a diffuse smear of lipid-stained material at the trailing edge of the pre-ß–migrating band. In some individuals, particularly those with combined hyperlipidemia and an apoE 3/2 or 4/2 phenotype,⁴³ these remnants form a second distinct, slow pre-ß–migrating band, this characteristic being referred to as "double pre-ß lipoproteinemia" (DPBL).²¹ In extreme cases, exemplified by patients with type III hyperlipoproteinemia, remnant lipoproteins are significantly enriched in apoE and cholesteryl ester, and they migrate (like LDL) with ß-mobility (ie, ß-VLDL; Figure 2).⁴⁴ Slow pre-ß VLDL have a particle diameter of 33 to 38 nm and are composed of 41% triglyceride, 26% cholesterol, 18% phospholipid, and 15% protein. Approximately 60% percent of this protein is apoB-100, 8% is apoE, and the remainder (30%) is composed of apoCs.²¹ The majority of ß-VLDL have a particle diameter of 35 to 110 nm. On average, they are more cholesterol rich than slow pre-ß VLDL, containing an average of 38% triglyceride, 34% cholesterol, 18% phospholipid, and 10% protein. They also differ from slow pre-ß VLDL by containing significant amounts of chylomicron remnants, as evidenced by the presence of apoB-48 (representing as much as one third of total ß-VLDL apoB).⁴⁵ From a clinical perspective, the measurement of plasma ß-VLDL (or slow pre-ß VLDL) is of limited diagnostic value, because time and expense are required to perform the ultracentrifugal isolation of VLDL fractions, subjective judgment is required to identify slow-migrating VLDL, and although densitometric scanning of lipid-stained lipoprotein bands or calculation of ß-VLDL cholesterol concentration with a formula⁴⁶ can be used to estimate the presence of remnant lipoproteins, slow-migrating VLDL are difficult to quantify accurately and objectively. Separation of remnant lipoproteins according to their charge, therefore, remains a qualitative rather than quantitative assessment of plasma remnant lipoprotein levels.

View larger version (43K): [in this window] [in a new window]   Figure 2. Separation of VLDL remnant lipoproteins by agarose gel electrophoresis. Total plasma, d<1.006 g/mL (VLDL) and d>1.006 g/mL (LDL+HDL) fractions are shown for a healthy subject, a patient with double prebeta-lipoproteinemia (DPBL), and a patient with type III hyperlipoproteinemia. The healthy subject was a 42-year-old male patient with a plasma cholesterol concentration of 6.23 mmol/L, a plasma triglyceride level of 2.02 mmol/L, and an HDL cholesterol level of 1.11 mmol/L. The DPBL patient was a 58-year-old female with a plasma cholesterol concentration of 6.49 mmol/L, a plasma triglyceride level of 5.56 mmol/L, and an HDL cholesterol level of 1.06 mmol/L. The type III patient was a 43-year-old male with a plasma cholesterol concentration of 9.83 mmol/L, a plasma triglyceride level of 7.00 mmol/L, and an HDL cholesterol level of 0.78 mmol/L. The point of sample application (origin) is indicated. Lipoprotein bands were lipid stained with Sudan black. The -, pre-ß–, and ß-migrating regions of the gel are also labeled. In the total plasma of the normolipidemic subject, these bands correspond to HDL, VLDL, and LDL, respectively. The band above -migrating HDL represents free fatty acids (FFA) bound to albumin. Two VLDL bands (pre-ß and slow pre-ß) are identifiable in the d<1.006 g/mL fraction of the DPBL patient. The slow pre-ß VLDL (remnant) band is indicated by an arrow and is also visible in total plasma. The slow pre-ß band of the DPBL patient migrates further than the ß-migrating remnant VLDL of the type III patient (also indicated by an arrow). Taken from Reference 43.

The best clinical evidence for the ability of ß-VLDL to promote atherosclerosis is provided by patients with type III hyperlipoproteinemia,¹² who have greatly increased plasma levels of ß-VLDL and increased risk of coronary and carotid artery atherosclerosis, as well as peripheral vascular disease.⁴⁷ Experimental animals fed diets containing large amounts of cholesterol also have increased circulating levels of cholesteryl ester–rich ß-VLDL. These lipoproteins are believed to be directly responsible for development of atherosclerosis because of their ability to induce lipid accumulation in cultured macrophages.⁴⁸ ß-VLDL isolated from dyslipidemic patients also cause macrophages in culture to take on the morphological characteristics of atherosclerotic foam cells, provided that these ß-VLDL contain apoE with normal receptor-binding characteristics.^{49 50} This is supported by results of experiments with J774 mouse macrophages showing that cholesteryl ester accumulation induced by VLDL (S_f 60 to 400) from hypertriglyceridemic (type IV) patients is substantially inhibited by the presence of anti-apoE monoclonal antibody.⁵¹ Most patients with elevated levels of ß-VLDL and type III hyperlipoproteinemia, however, are homozygous for a variant form of apoE (apoE2), which binds poorly to lipoprotein receptors owing to a single amino acid substitution (Arg158Cys).¹² Transgenic mice or rabbits expressing this form of apoE have increased levels of ß-VLDL and develop spontaneous atherosclerosis.^{52 53} Paradoxically, impaired binding of apoE2 to apoB/E receptors leads to poor macrophage recognition and uptake of apoE2-containing ß-VLDL and minimal cellular cholesterol accumulation.⁵¹ Consequently, it has been proposed that the potential atherogenicity of these lipoproteins resides in their susceptibility to oxidation, which promotes foam cell formation by a mechanism analogous to that which occurs with oxidized LDL.⁵⁴

	Separation of Remnant Lipoproteins According to Their Size

Top Abstract Introduction Difficulties in Detecting and... Remnant Lipoproteins Separated... Remnant Lipoproteins Separated... Separation of Remnant... Identification of Remnant... Quantification of Remnant... Remnant Lipoproteins Separated... Physical or Biochemical... Conclusions References

 
TRL remnants are intermediate in size between VLDL and LDLs and have been separated as "midband lipoproteins" (between bands of VLDL and LDL) by 3% polyacrylamide gel electrophoresis.⁵⁵ A similar separation can be achieved with 2% to 16% gradient gel electrophoresis.²⁸ Increased incidence of midband lipoproteins has been demonstrated in MI patients,³³ FH patients with angiographic evidence of CAD,⁵⁶ and FH patients with diabetes or impaired glucose tolerance.⁵⁷ More directly, these lipoproteins have been shown to be potentially atherogenic because they promote foam cell formation in cultured macrophages.⁵⁸ Preparative isolation of midband lipoproteins has not been performed, and therefore their biochemical characteristics have not been determined. It is nevertheless well accepted that IDLs, ß-VLDL, and lipoprotein(a) [Lp(a)] are intermediate in size between VLDL and LDLs and are thus isolated as midband lipoproteins. Because an increased Lp(a) concentration is associated with increased risk of atherosclerosis and thrombosis, its inclusion within midband lipoproteins may be advantageous from a diagnostic standpoint. On the other hand, this assay represents a nonspecific measure of remnant lipoproteins and, like agarose gel electrophoresis, is a means for detecting rather than accurately measuring TRL remnants.

	Identification of Remnant Lipoproteins According to Lipid Composition

Top Abstract Introduction Difficulties in Detecting and... Remnant Lipoproteins Separated... Remnant Lipoproteins Separated... Separation of Remnant... Identification of Remnant... Quantification of Remnant... Remnant Lipoproteins Separated... Physical or Biochemical... Conclusions References

 
Although TRL remnants cannot be isolated on the basis of their lipid composition, their presence in plasma can be estimated according to certain of their lipid components. For example, retinyl esters (RE) in the blood after the ingestion of a vitamin A–containing fat-rich meal have been used as markers for the presence of apoB-48–containing TRL of intestinal origin (chylomicrons and their remnants).^{59 60} The rationale for this approach is based on the concept that dietary vitamin A is esterified in the intestine and is incorporated into the core of chylomicron particles. These lipoproteins are secreted into intestinal lymph, and their component triglycerides are hydrolyzed by lipoprotein lipase. It is assumed that the majority of RE remain associated with chylomicrons during lipolysis and are taken up within chylomicron remnants via hepatic receptor–mediated processes. The liver does not resecrete RE, and they are either stored or resecreted as unesterified retinol molecules bound to retinol binding protein. The measurement of plasma RE concentration in the fed state has provided important insights into dietary lipid and plasma chylomicron clearance^{59 60 61 62 63} ; however, this approach cannot be considered an ideal measurement of circulating chylomicron remnants. First, the assumption that RE are always associated with apoB-48–containing lipoproteins is not totally accurate,⁶⁴ because RE can be detected in apoB-100–containing TRL⁶⁵ and in LDL and HDL at later postprandial time points.⁶⁶ Second, it is difficult to distinguish newly synthesized chylomicrons from chylomicron remnants, and even though ultracentrifugation has been used to separate larger, less-dense RE-containing lipoproteins from smaller remnant-like particles, this separation on the basis of density is somewhat arbitrary. Despite these limitations, several studies have demonstrated that patients with CAD, or at increased risk of CAD, have increased postprandial levels of RE.^{59 61 67 68 69 70 71 72}

A second approach has been to estimate the presence of remnant lipoproteins in the VLDL (d<1.006 g/mL) fraction of plasma by calculating the VLDL cholesterol–to-triglyceride ratio or alternatively, the ratio of VLDL cholesterol to total plasma triglyceride. The rationale behind this approach is that the presence of cholesteryl ester–enriched remnants in the VLDL fraction ought to be reflected by an increase in the ratio of VLDL cholesterol to triglyceride. The ratio of VLDL cholesterol to total plasma triglyceride has routinely been used as a diagnostic criteria for defining patients with type III hyperlipoproteinemia (ie, VLDL cholesterol/total triglyceride >0.3 for measurements in mg/dL or >0.7 for measurements in mmol/L).⁴⁴ Patients with combined hyperlipidemia and DPBL also have elevated VLDL cholesterol/total triglyceride molar ratios (0.57±0.11) compared with combined hyperlipidemia patients without DPBL (0.47±0.10), and these ratios are both significantly less than in patients with ß-VLDL (0.90±0.24).⁴³ Studies have shown that VLDL cholesterol–to-triglyceride ratios are significantly higher in patients with CAD^{33 73} and are related to the progression of coronary artery atherosclerosis and to clinical events related to CAD.³⁸

	Quantification of Remnant Lipoproteins According to Apolipoprotein Composition

Top Abstract Introduction Difficulties in Detecting and... Remnant Lipoproteins Separated... Remnant Lipoproteins Separated... Separation of Remnant... Identification of Remnant... Quantification of Remnant... Remnant Lipoproteins Separated... Physical or Biochemical... Conclusions References

 
ApoE plays a central role in controlling TRL metabolism by participating in the lipolytic conversion of TRL remnants to LDL^{74 75} and by acting as a specific ligand for receptor-mediated uptake of TRL remnants by the liver.⁷⁶ ApoE is consequently an important determinant of plasma remnant lipoprotein concentration, as illustrated by the pronounced accumulation of TRL remnants in patients with variant forms of apoE.⁷⁷ Although it cannot be considered to be a specific marker of plasma remnants, owing to its presence on nascent hepatic VLDL,⁷⁸ apoE is (under normal circumstances) a characteristic feature of TRL remnants.⁷⁹ Different assays have therefore measured the concentration of TRL containing apoE or the concentration of apoE associated with TRL. In the former case, 2 site-differential enzyme-linked immunosorbent assays (ELISAs) have been used to measure the amount of apoB associated with plasma lipoproteins containing apoE.^{80 81} In normolipidemic subjects, 20% of total plasma apoB is associated with apoE, decreasing to 15% in hypercholesterolemic subjects and increasing to as much as 30% in hypertriglyceridemic and 85% in type III hyperlipoproteinemic subjects. Higher levels of apoB associated with apoE (LpE:B) occur in VLDL than in IDL or LDL, and hypertriglyceridemic subjects have LpE:B levels 2-fold higher than control subjects.⁸⁰ LpE:B levels have been found to be significantly elevated in CAD case subjects compared with control subjects⁸² and to be higher in populations at greater risk of CAD.⁸³ Two-site ELISAs have similarly been used to measure apoE in apoB-containing lipoproteins (LpB:E).^{81 84} ApoE has also been measured in TRL fractions isolated by ultracentrifugation,^{85 86 87 88} gel filtration chromatography,^{89 90 91 92 93} or plasma precipitation.^{94 95} ApoE has been determined in remnant-like intermediate-sized lipoproteins (ISL) separated by gel filtration chromatography.⁹³ ISL apoE concentrations are particularly elevated in patients with combined hyperlipidemia or in patients with type III hyperlipoproteinemia. ISL apoE levels are significantly correlated with total triglyceride, cholesterol, and apoB and inversely related to HDL cholesterol levels. Plasma apoE-LpB concentration (measured as the difference between total plasma apoE and apoE in plasma made devoid of apoB-containing lipoproteins by immunoprecipitation) is also positively correlated with total cholesterol, VLDL cholesterol, and total triglyceride levels and inversely correlated with HDL cholesterol levels.⁹⁶ ApoE-LpB levels were found to be significantly higher in Irish but not in French MI survivors and to be higher in Irish than in French control subjects (Irish subjects being at significantly increased risk of MI). ApoE-LpB, however, was not found to be a statistically significant independent predictor of disease.⁹⁶ Sequential immunoaffinity chromatography or immunoprecipitation has revealed the existence of 3 major species of plasma lipoproteins containing both apoE and apoB⁹⁷ : LpB:C:E particles (ie, TRL containing apoC-I, C-II, C-III, and apoE); LpA-II:B:C:D:E particles (ie, TRL containing several apolipoproteins including apoA-II and apoE, characteristic of patients with Tangier disease or type V hyperlipoproteinemia⁹⁸ ); and LpB:E particles (ie, cholesteryl ester–enriched lipoproteins resembling LDL with apoE.⁹⁹ Two additional apoB-containing lipoproteins in human plasma are LpB:C particles (ie, TRL containing only C apolipoproteins) and LpB (ie, LDL containing only apoB¹⁰⁰ ). It remains to be determined which of these lipoprotein species best represents TRL remnants. One can argue that each of them has certain remnant characteristics, some being more indicative of newly formed remnants (eg, LpB:C) and others being more characteristic of end products of TRL catabolism (eg, LpB:E).⁹⁷ Ultimately, the final product of TRL catabolism is LDL or low-density LpB particles (lipoproteins with apoB-100 as their sole apolipoprotein and cholesteryl ester as their dominant neutral lipid), although these lipoproteins are not usually considered as remnants because they are not "intermediate" in their lipolytic conversion. The relative atherogenicity of different apoB-containing lipoproteins has not been completely elucidated,¹⁰¹ although elevated levels of all 3 TRL species (LpB:C, LpB:C:E, and LpA-II:B:C:D:E) have been linked to either the presence or severity of CAD.^{102 103}

Remnant lipoprotein accumulation can also occur in the absence of increased remnant apoE levels, as exemplified by the increased remnant levels of apoE-deficient individuals¹⁰⁴ and of apoE gene–knockout mice.^{105 106} The latter animals have provided significant evidence for a link between apoE, remnant lipoproteins, and atherogenesis.¹⁰⁷ Under normal circumstances, mice have low levels of VLDL and LDL cholesterol and carry the majority of their plasma cholesterol in HDL. They thus lack atherogenic lipoproteins and are relatively resistant to the development of atherosclerosis. Mice lacking apoE, however, are severely hypercholesterolemic, with average plasma cholesterol levels of 400 to 800 mg/dL on a regular chow diet. A large proportion of this cholesterol is carried in the VLDL plus IDL lipoprotein fractions. When fed a Western-type diet containing moderate amounts of cholesterol (0.15%) and fat (20%), they respond with even higher levels of VLDL and IDL and cholesterol levels of 1800 mg/dL. TRL and TRL-remnant clearance are severely impaired, consistent with the well-recognized function of apoE as a ligand for lipoprotein receptors. Atherosclerosis develops spontaneously in apoE-deficient animals, with the appearance of foam cell lesions as early as 8 weeks and more advanced, complex lesions (resembling those in human disease) after 15 weeks.^{108 109} Although it has been proposed that apoE deficiency can lead to foam cell formation through impaired apoE-mediated cellular cholesterol efflux,^{110 111} accumulating evidence suggests that atherogenesis is a result of increased oxidation of VLDL and IDL remnant particles.^{112 113 114}

ApoC-III is a second plasma apolipoprotein that plays an important role in TRL metabolism and whose plasma concentration and lipoprotein distribution have been used to assess the extent of plasma TRL catabolism.¹¹⁵ Plasma apoC-III concentration is strongly correlated with that of total plasma triglyceride,^{116 117 118} which reflects the ability of apoC-III to inhibit the activity of lipoprotein lipase^{119 120 121} and to inhibit the recognition and uptake of TRL remnants by the liver.^{122 123 124 125} ApoC-III also has the potential to inhibit hepatic lipase,¹²⁶ an enzyme that plays a critical role in the catabolism of both intestinal and hepatic TRL remnants.¹²⁷ Like apoE, TRL apoC-III has been quantified in terms of the concentration of TRL containing apoC-III^{80 101} or in terms of the concentration of apoC-III associated with TRL.^{84 96 116 117 118 128 129} Angiographic studies have provided evidence that under certain circumstances, levels of apoC-III in whole plasma or in TRL are associated with increased coronary^{130 131} or carotid^{132 133} artery atherosclerosis. Plasma lipoprotein distribution of apoC-III between TRL and HDL has also been independently related to the severity of CAD in normotensive, nondiabetic subjects¹⁰² and to the presence of CAD in subjects from France and Northern Ireland participating in the ECTIM study.⁹⁶ It must be remembered, however, that apoC-III can only be considered as a nonspecific marker of remnant lipoproteins, because it is unclear to what extent apoC-III in TRL represents the presence of large, innocuous TRL and to what extent it reflects the presence of smaller, potentially atherogenic TRL remnants. The lack of increase in atherosclerosis associated with plasma accumulation of large TRL in apoE gene–knockout mice overexpressing human apoC-III¹³⁴ and the only modest increase in extent of atherosclerosis in dietary cholesterol-fed mice overexpressing human apoC-III¹³⁵ provide experimental evidence for the association of apoC-III with larger, less-atherogenic TRL. In contrast, overexpression of human apoC-III in mice deficient in the LDL receptor results in the accumulation in plasma of smaller LDL-like (remnant) particles, which are in turn associated with increased development of atherosclerosis.¹³⁶

ApoB-48 is the major structural protein of chylomicrons secreted by the human small intestine and is an additional example of an apolipoprotein that has been used to measure the concentration of TRL and their remnants in circulating blood.¹³⁷ ApoB-48 is not produced by the human liver¹³⁸ and is therefore a specific marker for plasma chylomicrons (ie, TRL of intestinal origin). Thus, in normolipidemic subjects after an overnight fast, the plasma concentration of apoB-48 is very low (ie, 0.6±0.4 mg/L⁶⁴ or 2.5±1.2 mg/L¹⁴⁰ as measured by staining of apoB-48 separated by gradient slab gel electrophoresis; 0.46±0.27 mg/L as measured by ELISA¹⁴¹ ). This reflects a low basal rate of intestinal production of apoB-48–containing TRL, maintaining the enterohepatic transport of lipids. Within 3 hours after the ingestion of a fat-rich meal, plasma concentration of apoB-48 increases 5-fold and remains elevated for 6 to 8 hours after the meal.^{142 143} Fasting and postprandial levels of apoB-48 are 2- to 3-fold higher in patients with endogenous hypertriglyceridemia than in normolipidemic subjects.¹⁴⁴ Assessment of the risk of CAD by measurement of remnant lipoprotein levels 6 to 8 hours after meals is an attractive proposition considering that plasma triglyceride concentrations at these later postprandial time points have been shown to be independently predictive of disease.¹⁴⁵ Total plasma apoB-48 concentration is, however, a measure of both larger, relatively harmless chylomicrons as well as smaller, more noxious chylomicron remnants, which implies that apoB-48 needs to be measured in specific lipoprotein fractions if it is to be of prognostic value. This is borne out by evidence showing that apoB-48 levels in small chylomicron remnants (S_f 20 to 60) but not in larger TRL (S_f 60 to 400) are significantly related to the rate of progression of coronary lesions, as assessed by angiography.¹⁴⁶

	Remnant Lipoproteins Separated According to Their Apolipoprotein Immunospecificity

Top Abstract Introduction Difficulties in Detecting and... Remnant Lipoproteins Separated... Remnant Lipoproteins Separated... Separation of Remnant... Identification of Remnant... Quantification of Remnant... Remnant Lipoproteins Separated... Physical or Biochemical... Conclusions References

 
A system based on recognizing TRL remnants according to their apolipoprotein content and immunospecificity has been developed recently that provides a quantitative and clinically applicable approach to the measurement of plasma remnant lipoproteins. In this assay, remnant-like particles (RLP) are separated from plasma by immunoaffinity chromatography with a gel containing an anti–apoA-I and a specific apoB-100 monoclonal antibody (JI-H).^{147 148} The former antibody recognizes all HDL and any newly synthesized chylomicrons containing apoA-I, whereas the latter antibody recognizes all apoB-100–containing lipoproteins, except for certain particles enriched in apoE. The reason the anti–apoB-100 antibody does not recognize these latter apoE-enriched remnant-like lipoproteins is not entirely clear, although the amino acid sequence of the epitope region of the apoB-100 antibody is homologous to an amphipathic helical region of apoE, which suggests that apoE can compete for binding of the antibody to its epitope on apoB-100.¹⁴⁸ HDL, LDL, large chylomicrons, and the majority of VLDL are thus retained by the gel. The unbound RLP are made up of remnant-like VLDL containing apoB-100 and TRL containing apoB-48, which are routinely measured in terms of cholesterol, although they can also be quantified in terms of triglyceride or specific apolipoproteins (ie, apoB, apoC-III, or apoE¹⁴⁹ ).

Plasma concentration of RLP cholesterol has been shown to be significantly correlated with the plasma concentration of total triglyceride, VLDL triglyceride, and VLDL cholesterol. It is not strongly correlated with LDL cholesterol or LDL apoB.^{149 150} Median concentration of RLP cholesterol is 5.9 mg/dL (0.15 mmol/L) in 35- to 54-year-old American men and 4.6 mg/dL (0.12 mmol/L) in similarly-aged women.¹⁵¹ RLP cholesterol is higher in older versus younger subjects,^{147 150} men versus women,^{150 151} postmenopausal versus premenopausal women,¹⁵⁰ the fed versus the fasted state,^{152 153} individuals with diabetes,¹⁵⁴ patients with familial dysbetalipoproteinemia,^{147 155} hemodialysis patients,^{156 157} and patients with coronary artery restenosis after angioplasty.¹⁵⁸ It has been demonstrated that RLP cholesterol concentration is significantly higher in patients with CAD than in control subjects.^{147 151 159 160 161 162} The potential atherogenicity of RLP is supported by the observation that RLP can promote lipid accumulation by mouse peritoneal macrophages,¹⁶³ stimulate whole-blood platelet aggregation,^{164 165} and impair endothelium-dependent vasorelaxation.¹⁶⁶

Although certain physiological and pathophysiological aspects of the RLP fraction have been investigated, relatively little is known about the lipoprotein composition of this fraction and to what extent this composition varies from one individual to another. The physical and chemical properties of lipoproteins not recognized by the apoB-100 monoclonal antibody JI-H, subsequently isolated by ultracentrifugation at a density <1.006 g/mL, have been described, however.¹⁶⁷ These lipoproteins contained more molecules of apoE and cholesteryl esters than those that were bound, consistent with them being remnant-like lipoproteins. They had slow pre-ß electrophoretic mobility compared with the bound VLDL fraction and ranged in size from 25 to 80 nm. Other lipoproteins, however, may be present when the JI-H monoclonal antibody (together with an anti–apoA-I antibody) is used to isolate RLP by immunoaffinity chromatography from total plasma (in the absence of ultracentrifugation). High-performance liquid chromatographic analysis of RLP fractions isolated in this way from normolipidemic and diabetic subjects¹⁴⁸ and fast protein liquid chromatographic analysis of RLP from type III and type IV patients¹⁶⁸ have revealed considerable size heterogeneity in RLP, with particles ranging in size from VLDL to HDL. The relative amount of lipid and apolipoprotein in RLP can also vary considerably from one individual to another, with hypertriglyceridemic patients having more triglyceride and apoC-III and less apoE relative to apoB in RLP than normolipidemic subjects.¹⁴⁹ Hypertriglyceridemic patients invariably have elevated levels of RLP cholesterol, and the clinical usefulness of this assay will depend on future studies being able to show that RLP cholesterol concentration can predict the presence of coronary or carotid atherosclerosis independently of plasma triglyceride level.^{160 169}

	Physical or Biochemical Determinants of Remnant Atherogenicity

Top Abstract Introduction Difficulties in Detecting and... Remnant Lipoproteins Separated... Remnant Lipoproteins Separated... Separation of Remnant... Identification of Remnant... Quantification of Remnant... Remnant Lipoproteins Separated... Physical or Biochemical... Conclusions References

 
Despite the large number of clinical and experimental studies linking remnant lipoproteins and CAD, the question remains: what physical and/or biochemical characteristics are responsible for making these lipoproteins potentially atherogenic? Possible determinants of remnant atherogenicity have been mentioned in previous sections, but they can be summarized as follows.

Size and Number
In the initial stages of atherosclerosis, lipid accumulation in the artery wall is dependent on subendothelial entry and retention of lipid-rich lipoproteins.¹⁷⁰ The influx of lipoproteins into the intima increases directly with increasing lipoprotein concentration in plasma and decreases inversely with increasing lipoprotein diameter.¹⁷¹ Very large TRL (diameter >75 nm) thus appear to be too large to enter the vessel wall, whereas smaller, partially lipolyzed TRL have greater access.¹⁷² Fractional loss of lipoproteins from the intima is also dependent on size, meaning that VLDL, IDLs, and LDLs are retained in the intima to a greater extent than HDL or albumin.¹⁷³ It is significant that in both fasting diabetic and nondiabetic individuals, smaller TRL (S_f 12 to 60) are 4 to 6 times more prevalent in plasma than larger TRL (S_f 60 to 400) and that 70% of interindividual differences in plasma triglyceride concentration are due to differences in the number rather than the size of TRL.^{174 175}

ApoE
Cholesterol-loaded macrophages are a characteristic feature of developing atherosclerotic lesions and, as mentioned before, can be produced in vitro by incubating cultured macrophages with TRL and their remnants.⁴⁹ This has been shown to be a 2-step process⁵¹ whereby lipoprotein lipase secreted by macrophages hydrolyzes lipoprotein triglycerides and liberates free fatty acids, which are taken up and reesterified into triglycerides. The cholesteryl ester–enriched remnants are then taken up by a receptor-mediated mechanism mediated by apoE. Functional apoE is critical to this process, because cellular cholesteryl ester accumulation can be blocked with anti-apoE monoclonal antibody and does not occur with apoE2-containing ß-VLDL from type III hyperlipoproteinemic patients.^{50 51} The absolute amount of apoE on each remnant particle, the conformation of individual apoE molecules, and the presence of other remnant apolipoproteins may be important determinants. The pathophysiological relevance of apoE-mediated remnant uptake by macrophages in vivo, however, needs to be established, particularly because apoE is regarded as having antiatherogenic rather than proatherogenic properties.¹⁷⁶

Oxidizability
Evidence has been presented demonstrating that macrophage lipid accumulation can occur in the absence of apoE. For example, cellular cholesterol esterification and cholesteryl ester mass increase when macrophages are incubated with the VLDL/IDL fraction isolated from apoE gene–knockout mice.^{177 178} This effect may be due to apoE-independent binding of TRL to specific macrophage membrane-binding proteins^{179 180} or may be the result of cellular recognition and uptake of oxidized remnant lipoproteins. It has been shown that macrophage uptake of VLDL from type III and type IV patients is significantly enhanced by oxidation.^{54 181} Partial in vitro lipolysis of these VLDL caused increased susceptibility to oxidation and increased cellular cholesteryl ester accumulation. In vivo evidence for a link between remnant lipoprotein oxidation and atherosclerosis is provided by apoE gene–knockout mice, which have very high remnant levels, and very high autoantibody titers to epitopes of oxidized lipoproteins, such as malondialdehyde-lysine.^{112 182} Treatment of these animals with antioxidants, which had little effect on their plasma lipoprotein levels, was found to significantly reduce the extent of their atherosclerosis.^{113 114} Oxidized lipids may particularly be an atherogenic determinant of chylomicron remnants, on the basis of the hypothesis that oxidized lipids in the circulation can be derived from oxidized lipids in the diet. In rats, the level of oxidized lipids in mesenteric lymph chylomicrons and in the serum VLDL plus LDL fraction has been directly correlated with the quantity of oxidized lipids in the diet.¹⁸³ Similarly, higher levels of oxidized lipids have been found in serum chylomicrons of humans consuming diets high in oxidized fat.¹⁸⁴ Additional support for this concept is derived from rabbits fed an oxidized lipid (0.25% cholesterol) diet for 12 to 14 weeks, which were found to have increased oxidized lipid levels in their ß-VLDL (but not LDLs) and which had a 100% increase in aortic fatty streak lesions compared with rabbits fed a control (0.25% cholesterol) diet.¹⁸⁵

	Conclusions

Top Abstract Introduction Difficulties in Detecting and... Remnant Lipoproteins Separated... Remnant Lipoproteins Separated... Separation of Remnant... Identification of Remnant... Quantification of Remnant... Remnant Lipoproteins Separated... Physical or Biochemical... Conclusions References

 
In summary, plasma remnant lipoproteins of both hepatic and intestinal origin have been isolated and measured by use of a number of different biochemical methods and procedures. Each of these methods has contributed to our current understanding of the compositional characteristics of TRL remnants and their potential to promote atherosclerosis. Remnant lipoprotein parameters, however, cannot be considered to be equivalent, because some reflect the plasma concentration of larger, less completely catabolized TRL (eg, ß-VLDL), whereas others reflect smaller, more cholesterol-rich remnant lipoproteins (eg, IDLs). The relative atherogenicity of these different remnant species and the physical or biochemical characteristics that determine their atherogenicity have not been clearly defined. These topics need to be addressed by future studies. There is also an ongoing search for more accurate and clinically-applicable remnant lipoprotein assays, which will be able to better define the risk of CAD in patients with hypertriglyceridemia.

	Acknowledgments

 
We would like to thank Dr Petar Alaupovic for his helpful review and appraisal of our final manuscript. We would also like to acknowledge that research in our laboratory has been supported by the Medical Research Council of Canada (MT-14684), the Heart and Stroke Foundation of Canada, Parke-Davis, Merck Frosst, and Otsuka America Pharmaceutical, Inc, Rockville, Md.

Received November 10, 1998; accepted March 10, 1999.

	References

Top Abstract Introduction Difficulties in Detecting and... Remnant Lipoproteins Separated... Remnant Lipoproteins Separated... Separation of Remnant... Identification of Remnant... Quantification of Remnant... Remnant Lipoproteins Separated... Physical or Biochemical... Conclusions References

 
1. Gianturco SH, Bradley WA. Triglyceride-rich lipoproteins and their role in atherosclerosis. Curr Opin Lipidol.. 1991;2:324–328.

2. Havel R. McCollum Award Lecture, 1993: triglyceride-rich lipoproteins and atherosclerosis: new perspectives. Am J Clin Nutr.. 1994;59:795–759.[Free Full Text]

3. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol.. 1998;81:13B–17B.[Medline] [Order article via Infotrieve]

4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA.. 1993;269:3015–3023.[Abstract/Free Full Text]

5. Davignon J, Cohn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis.. 1996;124:S57–S64.

6. Gotto AM. Triglyceride: the forgotten risk factor. Circulation.. 1998;97:1027–1028.[Free Full Text]

7. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk.. 1996;3:213–219.[Medline] [Order article via Infotrieve]

8. Hulley SB. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med.. 1980;302:1383–1389.[Abstract]

9. Smith SJ, Cooper GR, Myers GL, Sampson EJ. Biological variability in concentrations of serum lipids: sources of variation among results from published studies and composite predicted values. Clin Chem.. 1993;39:1012–1022.[Abstract/Free Full Text]

10. Scheafer EJ, Levy RI, Anderson DW, Danner RN, Brewer HB Jr, Blackwelder WC. Plasma triglycerides in the regulation of HDL. Lancet.. 1978;2:391–393.[Medline] [Order article via Infotrieve]

11. Schonfeld G. Inherited disorders of lipid transport. Endocrinol Metab Clin North Am.. 1990;19:229–257.[Medline] [Order article via Infotrieve]

12. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill Publishing Co; 1989:1195–1213.

13. Nordestgaard BG, Nielsen LB. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol.. 1994;5:252–257.[Medline] [Order article via Infotrieve]

14. Ji Z-S, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem.. 1993;268:10160–10167.[Abstract/Free Full Text]

15. Evans AJ, Sawyez CG, Wolfe BM, Connelly PW, Maguire GF, Huff MW. Evidence that cholesteryl ester and triglyceride accumulation in J774 macrophages induced by very low density lipoprotein subfractions occurs by different mechanisms. J Lipid Res.. 1993;34:703–717.[Abstract]

16. Chung BH, Segrest JP, Smith K, Griffin FM, Brouillette CG. Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein: a possible mechanism of atherogenesis? J Clin Invest. 1989;83:1363–1374.

17. Rutledge JC, Woo MM, Rezai AA, Curtiss LK, Goldberg IJ. Lipoprotein lipase increases lipoprotein binding to the artery wall and increases endothelial layer permeability by formation of lipolysis products. Circ Res.. 1997;80:819–828.[Abstract/Free Full Text]

18. Mitropoulos KA, Miller GJ, Watts GF, Durrington PN. Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency. Atherosclerosis.. 1992;95:119–125.[Medline] [Order article via Infotrieve]

19. Eisenberg S. Remnant lipoprotein metabolism. In: Crepaldi G, Tiengo A, Manzato E, eds. Diabetes, Obesity and Hyperlipidemia: V. The Plurimetabolic Syndrome. New York, NY: Elsevier Science Publishers; 1993;7–14.

20. Mjøs OD, Faergeman O, Hamilton RL, Havel RJ. Characterization of remnants produced during the metabolism of triglyceride-rich lipoproteins of blood plasma and intestinal lymph in the rat. J Clin Invest.. 1975;56:603–615.

21. Pagnan A, Havel RJ, Kane JP, Kotite L. Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia. J Lipid Res.. 1977;18:613–622.[Abstract]

22. Cohn JS, Davignon J. Different approaches to the detection and quantification of triglyceride-rich lipoprotein remnants. In: Jacotot B, Mathé D, Fruchart JC, eds. Atherosclerosis XI. Singapore: Elsevier Science; 1998:771–776.

23. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitative analysis of serum lipoproteins. In: Nelson GJ, ed. Blood Lipids and Lipoproteins. New York, NY: John Wiley-Interscience; 1972:181–274.

24. Mabuchi H, Tatami R, Ueda K, Ueda R, Haba T, Kametani T, Watanabe A, Wakasugi T, Ito S, Koizumi J, Ohta M, Miyamoto S, Takeda R. Serum lipid and lipoprotein levels in Japanese patients with familial hypercholesterolemia. Atherosclerosis.. 1979;32:435–444.[Medline] [Order article via Infotrieve]

25. Avogaro P, Cazzolato G, Bittolo Bon G, Belussi F. Levels and chemical composition of HDL2, HDL3 and other major lipoprotein classes in survivors of myocardial infarction. Artery.. 1979;5:495–508.

26. Fontanais-Ferrer N, Serrat-Serrat J, Sorribas-Vivas A, Gonzalez-Garcia C, Gonzalez-Sastre F, Gomez-Gerique J. Quick method of determining lipoproteins, including those of intermediate density, in serum. Clin Chem.. 1988;34:1753–1757.[Abstract/Free Full Text]

27. Zhao S-P, Smelt AHM, Van den Maagdenberg AMJM, Van Tol A, Vroom TFFP, Gevers Leuven JA, Frants RR, Havekes LM, Van der Laarse A, Van't Hooft FM. Plasma lipoproteins in familial dys-betalipoproteinemia associated with apolipoproteins E2 (Arg158Cys), E3-Leiden, and E2(Lys146Gln), and effects of treatment with simvastatin. Arterioscler Thromb.. 1994;14:1705–1716.[Abstract/Free Full Text]

28. Musliner TA, Giotas C, Krauss RM. Presence of multiple subpopulations of lipoproteins of intermediate density in normal subjects. Arteriosclerosis.. 1986;6:79–87.[Abstract/Free Full Text]

29. Reardon MF, Fidge NH, Nestel PJ. Catabolism of the very low density lipoprotein B apolipoprotein in man. J Clin Invest.. 1978;61:850–860.

30. Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation.. 1987;75:124–130.[Abstract/Free Full Text]

31. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol.. 1996;16:697–704.[Abstract/Free Full Text]

32. Gofman JW, Lindgren F, Elliott H, Mantz W, Hewitt J, Strisower B, Herring V, Lyon TP. The role of lipids and lipoproteins in atherosclerosis. Science.. 1950;111:166–186.[Free Full Text]

33. Kameda K, Matsuzawa Y, Kubo M, Ishikawa K, Maejima I, Yamamura T, Yamamoto A, Tarui S. Increased frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan. Atherosclerosis.. 1984;51:241–249.[Medline] [Order article via Infotrieve]

34. Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T, Ito S, Koizumi J, Ohta M, Miyamoto S, Nakayama A, Kanaya H, Oiwake H, Genda A, Takeda R. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation.. 1981;64:1174–1184.[Abstract/Free Full Text]

35. Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation.. 1985;71:881–888.[Abstract/Free Full Text]

36. Krauss RM, Williams PT, Brensike J, Detre KM, Lindgren FT, Kelsey SF, Vranizan K, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet.. 1987;1:62–66.[Medline] [Order article via Infotrieve]

37. Watts GF, Mandalia S, Brunt JNH, Slavin BM, Coltart DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism.. 1993;42:1461–1467.[Medline] [Order article via Infotrieve]

38. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation.. 1993;88:2762–2770.[Abstract/Free Full Text]

39. Brensike JF, Levy RI, Kelsey SF. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation.. 1984;69:313–324.[Abstract/Free Full Text]

40. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet.. 1992;339:563–569.[Medline] [Order article via Infotrieve]

41. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, Selzer RH, Krauss RM. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation.. 1997;95:2022–2026.[Abstract/Free Full Text]

42. de Gennes JL, Dairou F, Hamon P, Truffert J. Ultracentrifugal evidence of a special subtype of mixed hyperlipidemia. Atherosclerosis.. 1977;27:493–497.[Medline] [Order article via Infotrieve]

43. Cohn JS, Giroux L-M, Fortin L-J, Davignon J. Prevalence of double pre-beta lipoproteinemia in hyperlipidemic patients is influenced by gender, menopausal status and apoE phenotype. Arterioscler Thromb Vasc Biol.. 1997;17:2630–2637.[Abstract/Free Full Text]

44. Morganroth J, Levy RI, Fredrickson DS. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med.. 1975;82:150–157.

45. Kane JP, Chen GC, Hamilton RL, Hardman DA, Malloy MJ, Havel RJ. Remnants of lipoproteins of intestinal and hepatic origin in familial dysbetalipoproteinemia. Arteriosclerosis. 1983;3:47–56.[Abstract/Free Full Text]

46. Hopkins PN, Wu LL, Schumacher MC, Emi M, Hegele RM, Hunt SC, Lalouel J-M, Williams RR. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2: evidence for a gene-gene interaction. Arterioscler Thromb.. 1991;11:1137–1146.[Abstract/Free Full Text]

47. Dobmeyer J, Lohrmann J, Feussner G. Prevalence and association of atherosclerosis at three different arterial sites in patients with type III hyperlipoproteinemia. Atherosclerosis.. 1996;119:89–98.[Medline] [Order article via Infotrieve]

48. Mahley RW. Atherogenic hyperlipoproteinemia: the cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol. Med Clin North Am.. 1982;66:375–402.[Medline] [Order article via Infotrieve]

49. Bersot TP, Innerarity TL, Mahley RW, Havel RJ. Cholesteryl ester accumulation in mouse peritoneal macrophages induced by ß-migrating very low density lipoproteins from patients with atypical dysbetalipoproteinemia. J Clin Invest.. 1983;72:1024–1033.

50. Huff MW, Sawyez CG, Connelly PW, Maguire GF, Little JA, Hegele RA. ß-VLDL in hepatic lipase deficiency induces apoE-mediated cholesterol ester accumulation in macrophages. Arterioscler Thromb.. 1993;13:1282–1290.[Abstract/Free Full Text]

51. Huff MW, Evans AJ, Sawyez CG, Wolfe BM, Nestel PJ. Cholesterol accumulation in J774 macrophages induced by triglyceride-rich lipoproteins: comparison of very low density lipoprotein from subjects with type III, IV, and V hyperlipoproteinemias. Arterioscler Thromb.. 1991;11:221–233.[Abstract/Free Full Text]

52. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human APOE*2. J Clin Invest.. 1998;102:130–135.[Medline] [Order article via Infotrieve]

53. Huang Y, Schwendner SW, Rall SC Jr, Sanan DA, Mahley RW. Apolipoprotein E2 transgenic rabbits: modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis. J Biol Chem.. 1997;272:22685–22694.[Abstract/Free Full Text]

54. Whitman SC, Miller DB, Wolfe BM, Hegele RA, Huff MW. Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation. Arterioscler Thromb Vasc Biol.. 1997;17:1707–1715.[Abstract/Free Full Text]

55. Mead MG, Dangerfield WG. The investigation of "mid-band" lipoproteins using polyacrylamide gel electrophoresis. Clin Chim Acta.. 1974;51:173–182.[Medline] [Order article via Infotrieve]

56. Tashiro J, Nishide T, Shinomiya M, Shirai K, Saito Y, Yoshida S, Yamashita M, Ohshima H, Murayama H. The "midband" lipoprotein is a coronary risk factor in Japanese patients with familial hypercholesterolaemia. Scand J Clin Lab Invest.. 1993;53:335–338.[Medline] [Order article via Infotrieve]

57. Yanagi K, Yamashita S, Kihara S, Nakamura T, Nozaki S, Nagai Y, Funahashi T, Kameda-Takemura K, Ueyama Y, Jiao S, Kubo M, Tokunaga K, Matsuzawa Y. Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance. Atherosclerosis.. 1997;132:43–51.[Medline] [Order article via Infotrieve]

58. Kawano M, Shinomiya M, Kanzaki T, Morisaki N, Shirai K, Saito Y, Yoshida S. Slow ß-migrating lipoprotein: an atherogenic subclass of low density lipoproteins. Clin Biochem.. 1996;29:241–248.[Medline] [Order article via Infotrieve]

59. Hazard WR, Bierman EL. Delayed clearance of chylomicron remnants following vitamin A-containing oral fat loads in broad-beta disease (type III hyperlipoproteinemia). Metabolism.. 1976;25:777–801.[Medline] [Order article via Infotrieve]

60. Berr F, Kern F Jr. Plasma clearance of chylomicrons labeled with retinol palmitate in healthy human subjects. J Lipid Res.. 1984;25:805–812.[Abstract]

61. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial metabolism in normals and type IIa, type III and type IV hyperlipoproteinemics: effects of treatment with cholestyramine and gemfibrozil. J Clin Invest.. 1987;79:1110–1119.

62. Weintraub MS, Eisenberg S, Breslow JL. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest.. 1987;80:1571–1577.

63. Weintraub MS, Zechner R, Brown A, Eisenberg S, Breslow JL. Dietary polyunsaturated fats of W-6 and W-3 series reduce postprandial lipoprotein levels: chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest.. 1988;82:1884–1893.

64. Karpe F, Bell M, Bjorkegren J, Hamsten A. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoprotein B-48 and B-100. Arterioscler Thromb Vasc Biol.. 1995;15:199–207.[Abstract/Free Full Text]

65. Cohn JS, Johnson EJ, Millar JS, Cohn SD, Milne RW, Marcel YL, Russell RM, Schaefer EJ. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res.. 1993;34:2033–2040.[Abstract]

66. Krasinski SD, Cohn JS, Russell RM, Schaefer EJ. Postprandial plasma vitamin A metabolism in humans: a reassessment of the use of plasma retinyl esters as markers for intestinally derived chylomicrons and their remnants. Metabolism.. 1990;39:357–365.[Medline] [Order article via Infotrieve]

67. Simpson HS, Williamson CM, Olivecrona T, Pringle S, Maclean J, Lorimer AR, Bonnefous F, Bogaievsky Y, Packard CJ, Shepherd J. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis.. 1990;85:193–202.[Medline] [Order article via Infotrieve]

68. Groot PHE, Van Stiphout WAHJ, Krauss XH, Jansen H, Van Tol A, Van Ramshorst E, Chin-On S, Hofman A, Cresswell SR, Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb.. 1991;11:653–662.[Abstract/Free Full Text]

69. Uiterwaal CSPM, Grobbee DE, Witteman JCM, van Stiphout W-AHJ, Krauss XH, Havekes LM, de Bruijn AM, van Tol A, Hofman A. Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann Intern Med.. 1994;121:576–583.[Abstract/Free Full Text]

70. Ginsberg HN, Jones J, Blaner WS, Thomas A, Karmally W, Fields L, Blood D, Begg MD. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol.. 1995;15:1829–1838.[Abstract/Free Full Text]

71. Sharrett AR, Chambless LE, Heiss G, Paton CC, Patsch W, for the ARIC Investigators. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol.. 1995;15:2122–2129.[Abstract/Free Full Text]

72. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, Liron M, Rubinstein A, Iaina A. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ. 1996;312:935–939.[Abstract/Free Full Text]

73. Avogaro P, Bittolo Bon G, Cazzolato G, Rorai E. Relationship between apolipoproteins and chemical components of lipoproteins in survivors of myocardial infarction. Atherosclerosis.. 1980;37:69–76.[Medline] [Order article via Infotrieve]

74. Chung BH, Segrest JP. Resistance of a very low density lipoprotein subpopulation from familial dysbetalipoproteinemia to in vitro lipolytic conversion to the low density lipoprotein fraction. J Lipid Res.. 1983;24:1148–1159.[Abstract]

75. Ehnholm C, Mahley RW, Chappell, Weisgraber KH, Ludwig E, Witztum JL. Role of apolipoprotein E in the lipolytic conversion of ß-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia. Proc Natl Acad Sci U S A. 1984;81:5566–5570.[Abstract/Free Full Text]

76. Herz J, Willnow TE. Lipoprotein and receptor interactions in vivo. Curr Opin Lipidol.. 1995;6:97–103.[Medline] [Order article via Infotrieve]

77. Mahley RW, Innerarity TL, Rall SC, Weisgraber KH, Taylor JM. Apolipoprotein E genetic variants provide insights into its structure and function. Curr Opin Lipidol.. 1990;1:87–95.

78. Hamilton RL, Moorehouse A, Havel RJ. Isolation and properties of nascent lipoproteins from highly purified rat hepatocytic Golgi fractions. J Lipid Res. 1991;32:529–543.[Abstract]

79. Ishikawa Y, Fielding C, Fielding PE. A change in apolipoprotein B expression is required for the binding of apolipoprotein E to very low density lipoprotein. J Biol Chem.. 1988;263:2744–2749.[Abstract/Free Full Text]

80. Kandoussi A, Cachera C, Parsy D, Bard JM, Fruchart JC. Quantitative determination of different apolipoprotein B containing lipoproteins by an enzyme linked immunosorbent assay: apoB with apoC-III and apoB with apoE. J Immunoassay.. 1991;12:305–323.[Medline] [Order article via Infotrieve]

81. Yang C-Y, Xie Y-H, Yang M, Quion JA, Gotto AM Jr. ELISA quantitation of apolipoproteins in plasma lipoprotein fractions: apoE in apoB-containing lipoproteins (Lp B:E) and apoB in apoE-containing lipoproteins (Lp E:B). J Protein Chem.. 1995;14:503–509.[Medline] [Order article via Infotrieve]

82. Genest JJ Jr, Bard JM, Fruchart J-C, Ordovas JM, Wilson PRW, Schaefer EJ. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis.. 1991;90:149–157.[Medline] [Order article via Infotrieve]

83. Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, Douste-Blazy P, Luc G, Richard JL, Ducimetiere P, Fruchart JC, Cambien F. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: the ECTIM Study. Arterioscler Thromb.. 1992;12:701–707.[Abstract/Free Full Text]

84. Alsayed N, Rebourcet R, Chapman J. Concentrations of apoprotein CII, CIII and E in total serum and in the apoprotein B-containing lipoproteins, determined by a new enzyme-linked immunosorbent assay. Clin Chem.. 1990;36:2047–2052.[Abstract/Free Full Text]

85. Blum CB, Aron L, Sciacca R. Radioimmunoassay studies of human apolipoprotein E. J Clin Invest.. 1980;66:1240–1250.

86. Havel RJ, Kotite L, Vigne J-L, Kane JP, Tun P, Phillips N, Chen GC. Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E: concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency. J Clin Invest.. 1980;66:1351–1362.

87. Falko JM, Schonfeld G, Witztum JL, Kolar JB, Weidman SW, Steelman R. Effects of diet on apolipoprotein E levels and on the apoprotein E subspecies in human plasma lipoproteins. J Clin Endocrinol Metab.. 1980;50:521–528.[Abstract/Free Full Text]

88. Milne RW, Doust-Blazy PH, Marcel YL, Retegui L. Characterization of monoclonal antibodies against human apolipoprotein E. J Clin Invest. 1981;68:111–117.

89. Gibson JC, Rubinstein A, Bukberg PR, Brown WV. Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects. J Lipid Res.. 1983;24:886–898.[Abstract]

90. Rubinstein A, Gibson JC, Paterniti JR Jr, Kakis G, Little A, Ginsberg HN, Brown WV. Effect of heparin-induced lipolysis on the distribution of apolipoprotein E among lipoprotein subclasses: studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase. J Clin Invest.. 1985;75:710–721.

91. Gibson JC, Rubinstein A, Brown WV, Ginsberg HN, Greten H, Norum R, Kayden H. ApoE-containing lipoproteins in low or high density lipoprotein deficiency. Arteriosclerosis.. 1985;1985:371–380.

92. Gibson JC, Goldberg RB, Rubinstein A, Ginsberg HN, Brown WV, Baker S, Joffe BI, Seftel HC. Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia. Arteriosclerosis.. 1987;7:401–407.[Abstract/Free Full Text]

93. Cohn JS, Tremblay M, Amiot M, Bouthillier D, Roy M, Genest J Jr, Davignon J. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol.. 1996;16:149–159.[Abstract/Free Full Text]

94. Castro GR, Fielding CJ. Evidence for the distribution of apolipoprotein E between lipoprotein classes in human normocholesterolemic plasma and for the origin of unassociated apolipoprotein E (Lp-E). J Lipid Res.. 1984;25:58–67.[Abstract]

95. Puchois P, Luley C, Alaupovic P. Comparison of four procedures for separating apolipoprotein A- and apolipoprotein B-containing lipoproteins in plasma. Clin Chem.. 1987;33:1597–1602.[Abstract/Free Full Text]

96. Luc G, Fievet C, Arveiler D, Evans AE, Bard J-M, Cambien F, Fruchart J-C, Ducimetiere P. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study: Etude Cas Temoins sur 'Infarctus du Myocarde. J Lipid Res.. 1996;37:508–517.[Abstract]

97. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins: characterization of ApoA- and ApoB-containing lipoprotein families. Prog Lipid Res.. 1991;30:105–138.[Medline] [Order article via Infotrieve]

98. Alaupovic P, Knight-Gibson C, Wang C-S, Downs D, Koren E, Brewer HB Jr, Gregg RE. Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia. J Lipid Res.. 1991;32:9–19.[Abstract]

99. Koren E, Alaupovic P, Lee DM, Dashti N, Kloer HU, Wen G. Selective isolation of human plasma low-density lipoprotein particles containing apolipoproteins B and E by use of a monoclonal antibody to apolipoprotein B. Biochemistry.. 1987;26:2734–2740.[Medline] [Order article via Infotrieve]

100. Bard JM, Candelier L, Agnani G, Clavey V, Torpier G, Steinmetz A, Fruchart JC. Isolation and characterization of human Lp-B lipoprotein containing apolipoprotein B as the sole apolipoprotein. Biochim Biophys Acta.. 1991;1082:170–176.[Medline] [Order article via Infotrieve]

101. Alaupovic P, Blackenhorn DH, Knight-Gibson C, Tavella M, Bard J-M, Shafer D, Lee ET, Brasuell J. ApoB-containing lipoprotein particles as risk factors for coronary artery disease. Adv Exp Med Biol.. 1990;285:299–309.

102. Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, McConathy WD, Alaupovic P. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis.. 1996;122:105–115.[Medline] [Order article via Infotrieve]

103. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol.. 1997;17:715–722.[Abstract/Free Full Text]

104. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, Brewer HB Jr. Familial apolipoprotein E deficiency. J Clin Invest.. 1986;78:1206–1219.

105. Zhang SH, Reddick RL, Pierdrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468–471.[Abstract/Free Full Text]

106. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343–353.[Medline] [Order article via Infotrieve]

107. Hofker MH, van Vlijmen BJM, Havekes LM. Transgenic mouse models to study the role of APOE in hyperlipidemia and atherosclerosis. Atherosclerosis.. 1998;137:1–11.[Medline] [Order article via Infotrieve]

108. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb.. 1994;14:133–140.[Abstract/Free Full Text]

109. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apoE: evaluation of lesional development and progression. Arterioscler Thromb.. 1994;14:141–147.[Abstract/Free Full Text]

110. Mazzone T. Apolipoprotein E secretion by macrophages: its potential physiological functions. Curr Opin Lipidol.. 1996;7:303–307.[Medline] [Order article via Infotrieve]

111. Von Eckardstein A. Cholesterol efflux from macrophages and other cells. Curr Opin Lipidol.. 1996;7:308–319.[Medline] [Order article via Infotrieve]

112. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb.. 1994;14:605–616.[Abstract/Free Full Text]

113. Pratico D, Tangirala RK, Rader DJ, Rokach J, Fitzgerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-deficient mice. Nat Med.. 1998;4:1189–1192.[Medline] [Order article via Infotrieve]

114. Hayek T, Attias J, Smith J, Breslow JL, Keidar S. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol.. 1998;31:540–544.[Medline] [Order article via Infotrieve]

115. Alaupovic P. David Rubinstein Memorial Lecture: the biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins. Can J Biochem.. 1981;59:565–579.[Medline] [Order article via Infotrieve]

116. Schonfeld G, George PK, Miller J, Reilly P, Witztum J. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism.. 1979;28:1001–1010.[Medline] [Order article via Infotrieve]

117. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim Biophys Acta.. 1980;617:503–513.[Medline] [Order article via Infotrieve]

118. Kashyap ML, Srivastava LS, Hynd BA, Gartside PS, Perisutti G. Quantitation of human apolipoprotein C-III and its subspecies by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein C-III subspecies concentrations in hypertriglyceridemia. J Lipid Res.. 1981;22:800–810.[Abstract]

119. Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun.. 1972;46:375–382.[Medline] [Order article via Infotrieve]

120. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest.. 1985;75:383–390.

121. Ginsberg HN, Le N-A, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest.. 1986;78:1287–1295.

122. Shelburne F, Hanks J, Meyers W, Quarfordt SA. Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J Clin Invest.. 1980;65:652–658.

123. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res.. 1985;26:556–563.[Abstract]

124. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem.. 1990;265:10771–10779.[Abstract/Free Full Text]

125. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol.. 1995;15:963–971.[Abstract/Free Full Text]

126. Kinnunen PKJ, Ehnholm C. Effect of serum and C apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett.. 1976;65:354–357.[Medline] [Order article via Infotrieve]

127. Hegele RA, Little JA, Vezina C, Maguire GF, Tu L, Wolever TS, Jenkins DJA, Connelly PW. Hepatic lipase deficiency: clinical, biochemical and molecular genetic characteristics. Arterioscler Thromb.. 1993;13:720–728.[Abstract/Free Full Text]

128. Graziani MS, Zanolla L, Righetti G, Marchetti C, Zanotto G, Lupo A. Distribution of CII and CIII peptides in lipoprotein classes: methods and clinical significance. Clin Chem.. 1994;40:240–244.[Abstract/Free Full Text]

129. Fredenrich A, Giroux L-M, Tremblay M, Krimbou L, Davignon J, Cohn JS. Plasma lipoprotein distribution of apoC-III in normolipidemic and hyperlipidemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J Lipid Res.. 1997;38:1421–1432.[Abstract]

130. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation.. 1990;81:470–476.[Abstract/Free Full Text]

131. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation.. 1994;90:42–49.[Abstract/Free Full Text]

132. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu C-r, Liu C-h, Mack WJ, Alaupovic P. Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four- year reduction of intima-media thickness measured by ultrasound. Circulation.. 1993;88:20–28.[Abstract/Free Full Text]

133. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C, Alaupovic P, Kwong-Fu H, Azen SP. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized, controlled clinical trial. Ann Intern Med.. 1996;124:548–556.[Abstract/Free Full Text]

134. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice: apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest.. 1997;99:2672–2681.[Medline] [Order article via Infotrieve]

135. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest.. 1995;96:2071–2074.

136. Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, Serajuddin H, Francone OL, Breslow JL, Tall AR. A mouse model with features of familial combined hyperlipidemia. Science.. 1997;275:391–394.[Abstract/Free Full Text]

137. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol.. 1994;5:102–109.[Medline] [Order article via Infotrieve]

138. Edge SB, Hoeg JM, Schneider PD, Brewer HB Jr. Apolipoprotein B synthesis in humans: liver synthesizes only apolipoprotein B-100. Metabolism.. 1985;34:726–730.[Medline] [Order article via Infotrieve]

139. Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS, Balasubramaniam S, Baron D, Branson J, Morgan J, Roy P. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis.. 1987;65:181–189.[Medline] [Order article via Infotrieve]

140. Kotite L, Bergeron N, Havel RJ. Quantification of apolipoproteins B-100, B-48, and E in human triglyceride-rich lipoproteins. J Lipid Res. 1995;36:890–900.[Abstract]

141. Lovegrove JA, Isherwood SG, Jackson KG, Williams CM, Gould BJ. Quantitation of apolipoprotein B-48 in triacylglycerol-rich lipoproteins by a specific enzyme-linked immunosorbent assay. Biochim Biophys Acta.. 1996;1301:221–229.[Medline] [Order article via Infotrieve]

142. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res. 1988;29:925–936.[Abstract]

143. Schneeman BO, Kotite L, Todd K, Havel RJ. Relationship between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci U S A. 1993;90:2069–2073.[Abstract/Free Full Text]

144. Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A. Metabolism of triglyceride-rich lipoproteins during alimentary lipemia. J Clin Invest.. 1993;91:748–758.

145. Patsch JR, Miesenböck G, Hopferwieser T, Mühlgerger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb. 1992;12:1336–1345.[Abstract/Free Full Text]

146. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994;106:83–97.[Medline] [Order article via Infotrieve]

147. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, Havel RJ. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta.. 1993;223:53–71.[Medline] [Order article via Infotrieve]

148. Nakajima K, Okazaki M, Tanaka A, Pullinger CR, Wang T, Nakano T, Adachi M, Havel RJ. Separation and determination of remnant-like particles in human serum using monoclonal antibodies to apoB-100 and apo AI. J Clin Ligand Assay.. 1996;19:177–183.

149. Marcoux C, Tremblay M, Jacques H, Krimbou L, Fredenrich A, Nakajima K, Davignon J, Cohn JS. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects. Atherosclerosis.. 1998;139:161–171.[Medline] [Order article via Infotrieve]

150. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PWF, Ordovas JM, Schaefer EJ. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. Cin Chem.. 1998;44:1224–1232.

151. Leary ET, Wang T, Baker DJ, Cilla DD, Zhong J, Warnick GR, Nakajima K, Havel RJ. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem.. 1998;44:2490–2498.[Abstract/Free Full Text]

152. Ikewaki K, Shige H, Nakajima K, Nakamura H. Postprandial remnant-like particles and coronary artery disease. In: Woodford FP, Davignon J, Sniderman A, eds. Atherosclerosis X. Amsterdam, Netherlands: Elsevier; 1995:200–202.

153. Tanaka A, Tomie N, Nakano T, Nakajima K, Yui K, Tamura M, Numano F. Measurement of postprandial remnant-like particles (RLP) following a fat-loading test. Clin Chim Acta.. 1998;275:43–52.[Medline] [Order article via Infotrieve]

154. Shimizu H, Mori M, Sato T. An increase of serum remnant-like particles in noninsulin-dependent diabetic patients with microalbuminuria. Clin Chim Acta.. 1993;221:191–196.[Medline] [Order article via Infotrieve]

155. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Murase T. A new approach for the detection of type III hyperlipoproteinemia by RLP-cholesterol assay. J Atheroscler Thromb.. 1994;1:30–36.[Medline] [Order article via Infotrieve]

156. Sekihara T, Nakano T, Nakajima K. High postprandial plasma remnant-like particles-cholesterol in patients with coronary artery diseases on chronic maintenance hemodialysis. Jpn J Nephrol.. 1996;38:220–228.

157. Oda H, Yorioka N, Okushin S, Nishida Y, Kushihata S, Ito T, Yamakido M. Remnant-like particles cholesterol may indicate atherogenic risk in patients on chronic hemodialysis. Nephron. 1997;76:7–14.[Medline] [Order article via Infotrieve]

158. Tanaka A, Ejiri N, Fujinuma Y, Yui K, Tamura M, Nakajima K, Morohoshi M, Fujisawa K, Uchimura I, Numano F. Remnant-like particles and restenosis of coronary arteries after PTCA. Ann N Y Acad Sci. 1995;748:595–598.[Medline] [Order article via Infotrieve]

159. Nakamura H, Ikewaki K, Nishiwaki M, Shige H. Postprandial hyperlipidemia and coronary artery disease. Ann N Y Acad Sci. 1995;748:441–446.[Medline] [Order article via Infotrieve]

160. McNamara JR, Shah PK, Nelson SM, Nakajima K, Wilson PWF, Schaefer EJ. Lipoprotein remnant cholesterol and triglyceride values in coronary cases and Framingham controls. Circulation. 1996;94(suppl I):I-94. Abstract.

161. Devaraj S, Vega G, Lange R, Grundy SM, Jialal I. Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. Am J Med. 1998;104:445–450.[Medline] [Order article via Infotrieve]

162. Takeichi S, Nakajima Y, Osawa M, Yukawa N, Saito T, Seto Y, Nakano T, Adachi M, Jitsukata K, Horiuchi K, Wang T, Nakajima K. The possible role of remnant-like particles as a risk factor for sudden cardiac death. Int J Legal Med. 1997;110:213–219.[Medline] [Order article via Infotrieve]

163. Tomono S, Kawazu S, Kato N, Ono T, Ishii C, Ito Y, Shimizu M, Shimoyama M, Nakano T, Nakajima K. Uptake of remnant like particles (RLP) in diabetic patients from mouse peritoneal macrophages. J Atheroscler Thromb.. 1994;1:98–102.[Medline] [Order article via Infotrieve]

164. Knöfler R, Nakano T, Nakajima K, Takada Y, Takada A. Remnant-like lipoproteins stimulate whole blood platelet aggregation in vitro. Thromb Res.. 1995;78:161–171.[Medline] [Order article via Infotrieve]

165. Mochizuki M, Takada TY, Urano T, Nagai N, Nakano T, Nakajima K, Tanaka A. The in vivo effects of chylomicron remnant and very low density lipoprotein remnant on platelet aggregation in blood obtained from healthy persons. Thromb Res.. 1996;5:583–593.

166. Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Kawano H, Ohta Y, Nakagawa O, Yoshimura M, Ogawa H, Matsumura T, Sugiyama S, Nakano T, Nakajima K, Yasue H. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation. 1998;97:2519–2526.[Abstract/Free Full Text]

167. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res.. 1992;33:369–380.[Abstract]

168. Marcoux C, Tremblay M, Nakajima K, Davignon J, Cohn JS. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. J Lipid Res. 1999;40:636–647.[Abstract/Free Full Text]

169. Karpe F, Bond GM, Hamsten A. Remnant-like lipoproteins concentration in plasma is strongly associated with early signs of carotid atherosclerosis in healthy 50-year old men. Circulation. 1998;98(suppl I):I-451. Abstract.

170. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol.. 1995;15:551–561.[Free Full Text]

171. Nordestgaard BG, Tybjaerg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits: roles of plasma concentration, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb.. 1992;12:6–18.[Abstract/Free Full Text]

172. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J Lipid Res.. 1988;29:1491–1500.[Abstract]

173. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol.. 1995;15:534–542.[Abstract/Free Full Text]

174. Poapst M, Reardon M, Steiner G. Relative contribution of triglyceride-rich lipoprotein particle size and number to plasma triglyceride concentration. Arteriosclerosis.. 1985;5:381–390.[Abstract/Free Full Text]

175. Steiner G, Tkac I, Uffelman KD, Lewis GF. Important contribution of lipoprotein particle number to plasma triglyceride concentration in type 2 diabetes. Atherosclerosis.. 1998;137:211–214.[Medline] [Order article via Infotrieve]

176. Davignon J, Cohn JS, Mabile L, Bernier L. Apolipoprotein E and atherosclerosis: insights from animal and human studies. Clin Chim Acta. In press.

177. Hendriks WL, van der Sman-de Beer F, van Vlijmen BJ, van Vark LC, Hofker MH, Havekes LM. Uptake by J774 macrophages of very-low-density lipoproteins isolated from apoE-deficient mice is mediated by a distinct receptor and stimulated by lipoprotein lipase. Arterioscler Thromb Vasc Biol. 1997;17:498–504.[Abstract/Free Full Text]

178. Hakamata H, Sakaguchi H, Zhang C, Sakashita N, Suzuki H, Miyazaki A, Takeya M, Takahashi K, Kitamura N, Horiuchi S. The very low- and intermediate-density lipoprotein fraction isolated from apolipoprotein E-knockout mice transforms macrophages to foam cells through an apolipoprotein E-dependent pathway. Biochemistry.. 1998;37:13720–13727.[Medline] [Order article via Infotrieve]

179. Gianturco SH, Ramprasad MP, Lin AH-Y, Song R, Bradley WA. Cellular binding site and membrane binding proteins for triglyceride-rich lipoproteins in human monocyte-macrophages and THP-1 monocytic cells. J Lipid Res. 1994;35:1674–1687.[Abstract]

180. Ramprasad MP, Li R, Bradley WA, Gianturco SH. Human THP-1 monocyte-macrophage membrane binding proteins: distinct receptor(s) for triglyceride-rich lipoproteins. Biochemistry.. 1995;34:9126–9135.[Medline] [Order article via Infotrieve]

181. Whitman SC, Sawyez CG, Miller DB, Wolfe BM, Huff MW. Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macrophage cholesteryl ester accumulation than oxidized LDL. J Lipid Res.. 1998;39:1008–1020.[Abstract/Free Full Text]

182. Palinski W, Hörkkö S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice: demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest.. 1996;98:800–814.[Medline] [Order article via Infotrieve]

183. Staprans I, Rapp JH, Pan X-M, Feingold KR. The effect of oxidized lipid in the diet on serum lipoprotein peroxides in control and diabetic rats. J Clin Invest.. 1993;92:638–643.

184. Staprans I, Rapp JH, Pan X-M, Kim KY, Feingold KR. Oxidized lipids in the diet are a source of oxidized lipid in chylomicrons of human serum. Arterioscler Thromb.. 1994;14:1900–1905.[Abstract/Free Full Text]

185. Staprans I, Rapp JH, Pan X-M, Hardman DA, Feingold KR. Oxidized lipids in the diet accelerate the development of fatty streaks in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol.. 1996;16:533–538.[Abstract/Free Full Text]

This article has been cited by other articles:

				L. Wang, R. Gill, T. L. Pedersen, L. J. Higgins, J. W. Newman, and J. C. Rutledge Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation J. Lipid Res., February 1, 2009; 50(2): 204 - 213. [Abstract] [Full Text] [PDF]

				K. Miyauchi, N. Kayahara, M. Ishigami, H. Kuwata, H. Mori, H. Sugiuchi, T. Irie, A. Tanaka, S. Yamashita, and T. Yamamura Development of a Homogeneous Assay to Measure Remnant Lipoprotein Cholesterol Clin. Chem., December 1, 2007; 53(12): 2128 - 2135. [Abstract] [Full Text] [PDF]

				H. J. Ting, J. P. Stice, U. Y. Schaff, D. Y. Hui, J. C. Rutledge, A. A. Knowlton, A. G. Passerini, and S. I. Simon Triglyceride-Rich Lipoproteins Prime Aortic Endothelium for an Enhanced Inflammatory Response to Tumor Necrosis Factor-{alpha} Circ. Res., February 16, 2007; 100(3): 381 - 390. [Abstract] [Full Text] [PDF]

				M. Okazaki, S. Usui, A. Fukui, I. Kubota, and H. Tomoike Component Analysis of HPLC Profiles of Unique Lipoprotein Subclass Cholesterols for Detection of Coronary Artery Disease Clin. Chem., November 1, 2006; 52(11): 2049 - 2053. [Abstract] [Full Text] [PDF]

				C. Imke, B. L. Rodriguez, J. S. Grove, J. R. McNamara, C. Waslien, A. R. Katz, B. Willcox, K. Yano, and J. D. Curb Are Remnant-Like Particles Independent Predictors of Coronary Heart Disease Incidence?: The Honolulu Heart Study Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1718 - 1722. [Abstract] [Full Text] [PDF]

				R. J Cheung, E. K Gupta, and M. K Ito Acute Coffee Ingestion Does Not Affect LDL Cholesterol Level Ann. Pharmacother., July 1, 2005; 39(7): 1209 - 1213. [Abstract] [Full Text] [PDF]

				P. N. Hopkins, L. L. Wu, S. C. Hunt, and E. A. Brinton Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1003 - 1012. [Abstract] [Full Text] [PDF]

				J. S. Cohn, C. Rodriguez, H. Jacques, M. Tremblay, and J. Davignon Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE J. Lipid Res., August 1, 2004; 45(8): 1572 - 1579. [Abstract] [Full Text] [PDF]

				H. Fukushima, S. Sugiyama, O. Honda, S. Koide, S. Nakamura, T. Sakamoto, M. Yoshimura, H. Ogawa, D. Fujioka, and K. Kugiyama Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type ii diabetes mellitus J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2219 - 2224. [Abstract] [Full Text] [PDF]

				K. Oi, H. Shimokawa, J. Hiroki, T. Uwatoku, K. Abe, Y. Matsumoto, Y. Nakajima, K. Nakajima, S. Takeichi, and A. Takeshita Remnant Lipoproteins from Patients with Sudden Cardiac Death Enhance Coronary Vasospastic Activity Through Upregulation of Rho-Kinase Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 918 - 922. [Abstract] [Full Text]

				T.B. Twickler, G.M. Dallinga-Thie, J.S. Cohn, and M.J. Chapman Elevated Remnant-Like Particle Cholesterol Concentration: A Characteristic Feature of the Atherogenic Lipoprotein Phenotype Circulation, April 27, 2004; 109(16): 1918 - 1925. [Full Text] [PDF]

				T. B. Twickler, M. J. M. Cramer, G. M. Dallinga-Thie, M. J. Chapman, D. W. Erkelens, and H. P. F. Koppeschaar Adult-Onset Growth Hormone Deficiency: Relation of Postprandial Dyslipidemia to Premature Atherosclerosis J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2479 - 2488. [Full Text] [PDF]

				S. M. Grundy Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy Circulation, November 12, 2002; 106(20): 2526 - 2529. [Full Text] [PDF]

				I. Jialal and S. Devaraj Remnant Lipoproteins: Measurement and Clinical Significance Clin. Chem., February 1, 2002; 48(2): 217 - 219. [Full Text] [PDF]

				D. T. Stein, S. Devaraj, D. Balis, B. Adams-Huet, and I. Jialal Effect of Statin Therapy on Remnant Lipoprotein Cholesterol Levels in Patients With Combined Hyperlipidemia Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 2026 - 2031. [Abstract] [Full Text] [PDF]

				T. C. Ooi, M. Cousins, D. S. Ooi, G. Steiner, K. D. Uffelman, K. Nakajima, and I. E. Simo Postprandial Remnant-like Lipoproteins in Hypertriglyceridemia J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3134 - 3142. [Abstract] [Full Text] [PDF]

				P. J. Nestel, H. Shige, S. Pomeroy, M. Cehun, and J. Chin-Dusting Post-prandial remnant lipids impair arterial compliance J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1929 - 1935. [Abstract] [Full Text] [PDF]

				H. W Wilmink, M. B Twickler, J. D. Banga, G. M Dallinga-Thie, H. Eeltink, D.W. Erkelens, T. J Rabelink, and E. S Stroes Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles Cardiovasc Res, June 1, 2001; 50(3): 577 - 582. [Abstract] [Full Text] [PDF]

				C. Marcoux, P. N. Hopkins, T. Wang, E. T. Leary, K. Nakajima, J. Davignon, and J. S. Cohn Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state J. Lipid Res., September 1, 2000; 41(9): 1428 - 1436. [Abstract] [Full Text]

				S. Hirany, D. O'Byrne, S. Devaraj, and I. Jialal Remnant-like Particle-Cholesterol Concentrations in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease Clin. Chem., May 1, 2000; 46(5): 667 - 672. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohn, J. S. Articles by Davignon, J. Search for Related Content PubMed PubMed Citation Articles by Cohn, J. S. Articles by Davignon, J. Related Collections Pathophysiology Risk Factors Lipid and lipoprotein metabolism